Pharsight

Bendeka generic

Bendeka is an anti-cancer drug owned by Eagle Pharmaceuticals. This drug, which contains bendamustine hydrochloride as its active ingredient, was first authorized for market use on December 7, 2015, and is available in a solution for intravenous infusion.

When will Bendeka generic be available?

Based on the expiration of the last patent (US6717274) held by Eagle Pharmaceuticals, the generic version of Bendeka may likely be released after March 15, 2033. This implies no competition for Bendeka until that date.

Bendeka uses

Bendeka is used for the treatment of patients with indolent B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Thanks to its active ingredient, bendamustine hydrochloride, Bendeka can effectively interfere with the growth of cancer cells in the body, helping to suppress the disease.

Bendeka patent expiration

Bendeka has a total of 16 drug patents in the United States. These patents secure the drug from the competition until the final one expires on March 15, 2033. Below are the details of the patent:

EPO Oppostions filed on Bendeka

Litigations filed on Bendeka

Bendeka dosage

Want to ask something?